One physician describes how his informed consent process was the deciding factor in a missed case of prostate cancer, and outlines how any physician can accomplish it. ... In 1990, Dr. Gottesman was sued for late diagnosis of a patient's prostate cancer.
2. Prostate cancer is still a leading cancer killer for men in the U.S. ... 2. Just because you are diagnosed with prostate cancer, doesn't mean you need to treat it.
HPV is the most common sexually-transmitted disease and aside from causing cervical cancer is also the cause of genital warts. ... to 26 that immunize them from the subtypes of HPV that cause cancer.
African-American men have a much higher rate of aggressive prostate cancer and men in high risk groups may get higher benefit from these tests. ... The American Cancer Society estimates that 241,740 men will be diagnosed with prostate cancer this year,
Fish oil causes prostate cancer, except that it doesn’t.
to. When it came back at 4.10 ng/dL (threshold 4.00), he went for biopsy (what else to do?) which showed low grade, gland-confined prostate cancer. ... Or George, who dutifully came yearly for his digital rectal exam, got his PSA, and when his biopsy
An expanded approval of abiraterone acetate (Zytiga) to treat metastatic castration-resistant prostate cancer prior to chemotherapy. ... The drug was initially approved in November 2011 for use in patients whose prostate cancer progressed after treatment
There are two basic problems with cancer screening in general, problems that pertain as much or more to prostate cancer as to breast cancer. ... This is true of many prostate cancers as well, and the reason for formal recommendations against routine
For prostate cancer, the SEER data show a median age of 67 years at diagnosis, and for death from prostate cancer, 80 years. ... So the potential number of life-years saved by early detection and intervention is, on average, greater for breast cancer
Cabazitaxel (Jevtana), a chemotherapy drug used with prednisone for prostate cancer. ... It is the first treatment for advanced, hormone-refractory prostate cancer that has worsened during or after treatment with docetaxel.